Moderna (NASDAQ:MRNA) Hits New 52-Week High – Here’s Why

Moderna, Inc. (NASDAQ:MRNA)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $56.60 and last traded at $53.86, with a volume of 5328518 shares traded. The stock had previously closed at $49.83.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Settlement clears litigation overhang — Moderna reached an agreement that resolves global disputes tied to its COVID vaccine, removing a major legal cloud that had pressured the stock and letting the company refocus on development and commercialization. Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang
• Positive Sentiment: EU regulatory boost for combo vaccine — An EU CHMP positive opinion for Moderna’s mCombriax (COVID‑flu combo) improves the company’s near‑term commercial outlook in Europe and supports future vaccine revenue diversification. Moderna’s dual Covid-flu vaccine poised for EMA approval on positive CHMP take
• Neutral Sentiment: Market reaction and coverage — Broad market stories and premarket movers lists note Moderna among top gainers as the settlement and regulatory news hit headlines, helping momentum but not adding new fundamental data. Moderna and Ross Stores Lead Stock Gainers on Wednesday
• Neutral Sentiment: Investor/analyst context — Recent conference presentations and write‑ups revisit Moderna’s valuation, oncology programs and cash runway; these provide context for longer‑term upside but won’t immediately change near‑term fundamentals. Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Negative Sentiment: Material cash/earnings impact and contingencies — Moderna will record a significant charge (reports cite an initial $950M payment with potential exposure up to $2.25B) in Q1 to resolve the disputes; the company also plans an appeal arguing limited liability, so contingent liabilities and near‑term cash guidance were updated. Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant
• Negative Sentiment: Underlying business risks remain — Analysts and commentators continue to flag the steep post‑pandemic revenue decline, reliance on upcoming Phase‑3 oncology readouts and regulatory/commercial execution as key risks that could limit a durable rerating absent positive clinical results. Moderna Stock (MRNA): Is It a Buy Now? 7 Questions After the Crash

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. BMO Capital Markets raised shares of Moderna from a “market perform” rating to a “buy” rating in a research report on Monday, January 12th. Jefferies Financial Group set a $37.00 target price on Moderna and gave the company a “hold” rating in a research report on Tuesday. Berenberg Bank set a $28.00 target price on shares of Moderna in a research report on Monday, November 17th. Wall Street Zen upgraded shares of Moderna from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. Finally, Morgan Stanley set a $30.00 target price on Moderna in a report on Monday, February 16th. Two analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and five have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average price target of $32.33.

Moderna Stock Performance

The stock has a market capitalization of $21.65 billion, a P/E ratio of -7.54 and a beta of 1.29. The company’s fifty day simple moving average is $41.78 and its two-hundred day simple moving average is $31.72. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.22 and a current ratio of 3.29.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, February 13th. The company reported ($2.11) earnings per share for the quarter, topping the consensus estimate of ($2.79) by $0.68. Moderna had a negative return on equity of 30.15% and a negative net margin of 145.16%.The business had revenue of $678.00 million during the quarter, compared to analysts’ expectations of $611.14 million. During the same period last year, the firm posted ($2.91) EPS. The firm’s revenue for the quarter was down 33.2% compared to the same quarter last year. As a group, equities analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Insider Buying and Selling at Moderna

In related news, Director Noubar Afeyan sold 23,853 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $29.48, for a total transaction of $703,186.44. Following the completion of the sale, the director owned 3,924 shares of the company’s stock, valued at $115,679.52. This represents a 85.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, President Stephen Hoge sold 160,009 shares of the firm’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the completion of the transaction, the president directly owned 1,457,427 shares in the company, valued at approximately $71,180,734.68. This represents a 9.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 184,366 shares of company stock worth $8,531,936. 10.90% of the stock is currently owned by insiders.

Institutional Trading of Moderna

Several large investors have recently made changes to their positions in MRNA. Rothschild Investment LLC lifted its stake in Moderna by 94.1% during the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock worth $25,000 after purchasing an additional 446 shares during the last quarter. Atlantic Union Bankshares Corp acquired a new position in shares of Moderna during the 2nd quarter worth $26,000. MUFG Securities EMEA plc bought a new stake in shares of Moderna during the 2nd quarter worth $28,000. Flagship Harbor Advisors LLC bought a new position in Moderna in the fourth quarter valued at about $31,000. Finally, Ameriflex Group Inc. raised its stake in Moderna by 3,775.0% during the third quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock worth $32,000 after acquiring an additional 1,208 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.